EXACT Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. Read more about EXACT Sciences.
Diagnostics for the early detection and prevention of colon cancer
Exact Sciences Closes $8.2-Million Private Placement, Enters Into Licensing and Collaboration Agreement
Thursday, June 11th, 2009Contacts:
Maneesh K. Arora
Chief Financial Officer, Exact Sciences Corp.
+1 508 683-1200
Kathy Anderson
Mayo Clinic Dept. of Public Affairs
+1 507 284-5005
For Immediate Release
MARLBOROUGH, Mass., June 11, 2009 – Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into a collaboration and license agreement with Mayo Clinic. Exact also announced that it has closed an $8.2-million private [...]
To save lives by launching an FDA-cleared, patient friendly colorectal-cancer-screening test that detects both pre-cancer and cancer